American Journal of Cardiology
Volume 104, Issue 12 , Pages 1689-1694 , 15 December 2009

Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy†

  • Gregory A. Nichols, PhD

      Affiliations

    • Kaiser Permanente Center for Health Research, Portland, Oregon
    • Corresponding Author InformationCorresponding author: Tel: 503-335-6733; fax: 503-335-6311
    • ,
  • Baishali M. Ambegaonkar, PhD

      Affiliations

    • Merck & Company, Inc., Whitehouse Station, New Jersey
    • ,
  • Vasilisa Sazonov, PhD

      Affiliations

    • Merck & Company, Inc., Whitehouse Station, New Jersey
    • ,
  • Jonathan B. Brown, MPP, PhD

      Affiliations

    • Kaiser Permanente Center for Health Research, Portland, Oregon

Received 6 June 2009 ,Revised 29 July 2009 ,Accepted 29 July 2009.

References 

  1. Grant RW, Meigs JB. Prevalence and treatment of low HDL Cholesterol among primary care patients with type 2 diabetes: An unmet challenge for cardiovascular risk reduction. Diabetes Care. 2007;30:479–484
  2. Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154:554–560
  3. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293–298
  4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  5. Grundy SM, Cleeman JI, Bairey-Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  6. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adult with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003–2004. Am Heart J. 2008;156:112–119
  7. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  8. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention study. Circulation. 2000;102:21–27
  9. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706–714
  10. Kastelein JJP, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–3009
  11. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  12. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA. 2008;299:1561–1573
  13. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R, Kondos GT, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008;117:2123–2130
  14. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467
  15. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676–683
  16. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–563
  17. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol. 2001;87:646–649
  18. Afonso NW, Nassif G, Aranha ANF, DeLor B, Cardozo LJ. Low-density lipoprotein cholesterol goal attainment among high risk patients: does a combined intervention targeting patients and providers work?. Am J Manag Care. 2006;12:589–594

 This study was funded by Merck & Company, Inc., Whitehouse Station, New Jersey.

PII: S0002-9149(09)01483-0

doi: 10.1016/j.amjcard.2009.07.050

American Journal of Cardiology
Volume 104, Issue 12 , Pages 1689-1694 , 15 December 2009

Article Tools

* Image Usage & Resolution